沃华医药(002107) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥195,893,641.58, a decrease of 26.55% compared to the same period last year[3]. - The net profit attributable to shareholders for the same period was ¥35,063,007.74, down 29.92% year-on-year[3]. - The basic earnings per share decreased by 33.33% to ¥0.06, while the diluted earnings per share also fell by 33.33% to ¥0.06[3]. - The total profit for Q3 2021 was approximately ¥156.27 million, a decrease from ¥177.49 million in the same period last year, representing a decline of about 11.5%[19]. - The net profit for Q3 2021 was approximately ¥140.07 million, compared to ¥146.65 million in Q3 2020, reflecting a decrease of about 4.5%[19]. - The total comprehensive income attributable to the parent company for Q3 2021 was approximately ¥136.88 million, compared to ¥140.60 million in Q3 2020, a decrease of about 2.6%[19]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,147,152,457.54, a decline of 16.27% from the previous year-end[3]. - Total assets decreased to RMB 1,147,152,457.54 from RMB 1,370,094,900.45, a decline of 21.6%[16]. - Total liabilities decreased to RMB 239,140,622.02 from RMB 452,080,444.01, a reduction of 47.2%[16]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥145,888,137.53, an increase of 14.88%[3]. - The cash flow from operating activities for Q3 2021 was approximately ¥145.89 million, an increase from ¥126.99 million in the previous year, indicating a growth of about 14.9%[21]. - The cash outflow from investing activities for Q3 2021 was approximately ¥17.07 million, compared to an inflow of ¥55.21 million in the same period last year[22]. - The cash outflow from financing activities for Q3 2021 was approximately ¥343.69 million, significantly higher than the outflow of ¥45.76 million in Q3 2020[22]. Equity and Other Income - The company's total equity attributable to shareholders decreased by 1.63% to ¥794,200,585.69[3]. - The company reported a significant increase in other income to RMB 11,796,475.58, compared to RMB 3,743,698.04 in the same period last year[18]. - The company reported a significant increase in government subsidies, with other income rising by 215.10% to ¥11,796,475.58[9]. Expenses - Research and development expenses increased by 30.57% to ¥40,069,849.45, reflecting increased investment in quality standards and clinical research[9]. - Management expenses rose by 39.12% to ¥36,347,298.44, mainly due to increased personnel costs and depreciation from a new facility[8]. - Research and development expenses increased to RMB 40,069,849.45, representing a rise of 30.5% compared to RMB 30,689,012.76 in the same period last year[18]. Cash and Cash Equivalents - Cash and cash equivalents decreased by 43.96% to ¥277,098,153.01, primarily due to cash dividends and bank loan repayments[8]. - Cash and cash equivalents decreased significantly to RMB 277,098,153.01 from RMB 494,426,490.02 at the end of 2020, a decline of 43.8%[14]. - The total cash and cash equivalents at the end of Q3 2021 were approximately ¥273.99 million, down from ¥521.78 million at the end of Q3 2020, a decrease of about 47.5%[22]. Accounts Receivable and Inventory - Accounts receivable decreased to RMB 95,765,626.76 from RMB 115,511,756.12, a reduction of 17.1%[14]. - Inventory increased to RMB 151,730,152.13, up 32.3% from RMB 114,643,446.09 at the end of 2020[15]. Audit Status - The company did not undergo an audit for the Q3 2021 report[24].